Lineage Cell Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 12, 2026
LCTX$1.04-3.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
(IN THOUSANDS, EXCEPT PER SHARE DATA)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| REVENUES: | ||
| Collaboration revenues | $1,575 | $1,270 |
| Royalties, license and other revenues | 150 | 232 |
| Total revenues | 1,725 | 1,502 |
| OPERATING EXPENSES: | ||
| Cost of royalties | — | 36 |
| Research and development | 4,234 | 3,114 |
| General and administrative | 5,084 | 4,857 |
| Total operating expenses | 9,318 | 8,007 |
| Loss from operations | (7,593) | (6,505) |
| OTHER INCOME (EXPENSES): | ||
| Interest income, net | 405 | 478 |
| Gain (loss) on marketable equity securities, net | 24 | (5) |
| Change in fair value of warrant liability | 2,324 | 2,305 |
| Foreign currency transaction gain (loss), net | 50 | (231) |
| Other income (expense), net | 1 | (185) |
| Total other income (expenses) | 2,804 | 2,362 |
| NET LOSS | (4,789) | (4,143) |
| Net (income) loss attributable to noncontrolling interest | (23) | 4 |
| NET LOSS ATTRIBUTABLE TO LINEAGE | $(4,812) | $(4,139) |
| NET LOSS PER COMMON SHARE ATTRIBUTABLE TO LINEAGE: | ||
| Basic | $(0.02) | $(0.02) |
| Diluted | $(0.03) | $(0.02) |
| WEIGHTED-AVERAGE COMMON SHARES USED TO COMPUTE NET LOSS PER COMMON SHARE: | ||
| Basic | 245,029 | 226,054 |
| Diluted | 261,175 | 226,054 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.